Perspective

40th anniversary of essential medicines: a loud call for improving its access

Published in: Volume 6 / Year 2017 / Issue 4
Author(s): , ,
Page: 174-7

Author byline as per print journal: Mohammad Bashaar, PhD; Professor Mohamed Azmi Hassali, PhD; Fahad Saleem, PhD Abstract: The soaring costs of medicine are a global dilemma. It was hoped that the… Read More »

Pharmacovigilance of biosimilars and other biologicals within the hospital: current practices and future challenges

Published in: Volume 6 / Year 2017 / Issue 1
Author(s): , ,
Page: 24-6

Author byline as per print journal: Barbara OM Claus, PharmD, PhD; Tiene Bauters, PharmD, PhD; Annemie Somers, PharmD, PhD Abstract: In the coming decade, many patents for biological pharmaceuticals will expire.… Read More »

Biosimilars in Italy: a gastroenterologist’s view

Published in: Volume 5 / Year 2016 / Issue 3
Author(s): , ,
Page: 131-3

Author byline as per print journal: Vito Annese, MD; Tommaso Gabbani, MD; Antonio Luca Annese, MD Abstract: The introduction of biological therapy has revolutionized the paradigm of treatment in the… Read More »

Are the perspectives regarding the use of biosimilars in the setting of haematology and blood and marrow transplant changing?

Published in: Volume 5 / Year 2016 / Issue 3
Author(s):
Page: 128-30

Introduction: Canada is among the leading spenders in pharmaceuticals. Based on projected figures, the cost of pharmaceuticals is expected to rise by another 6–12% by 2023. Approximately CAN$4.6 billion of… Read More »

Regional management of biosimilars in Germany

Published in: Volume 5 / Year 2016 / Issue 3
Author(s):
Page: 125-7

Abstract: Biosimilars of tumour necrosis factor-alpha (TNF-α) inhibitors, such as infliximab or etanercept, have recently entered the market. The management of these new products by the healthcare systems differ between… Read More »

Pharmacovigilance on biologicals and biosimilars: a Danish perspective

Published in: Volume 5 / Year 2016 / Issue 3
Author(s):
Page: 123-4

Abstract: The development of biological medicinal products is in rapid growth and as patents for reference products expire, new biosimilar products become available. This has a marked impact on several… Read More »

Importance of manufacturing consistency of the glycosylated monoclonal antibody adalimumab (Humira®) and potential impact on the clinical use of biosimilars

Published in: Volume 5 / Year 2016 / Issue 2
Author(s): ,
Page: 70-3

Author byline as per print journal: Professor Paul J Declerck, PhD; Paul W Tebbey, PhD Abstract: The clinical performance of biological therapies is affected by their manufacturing processes. The advent… Read More »

New monoclonal antibody biosimilars approved in 2015 in Latin America: position statement of the Latin American Forum on Biosimilars on biosimilarity, interchangeability and extrapolation of indications

Published in: Volume 5 / Year 2016 / Issue 2
Author(s): , , , ,
Page: 66-9

Author byline as per print journal: Valderílio Feijó Azevedo1,2, Alejandra Babini3,4, Fabio Vieira Teixeira5,6, Igor Age Kos1,2, Pablo Matar7 Introduction: The Latin American Forum on Biosimilars (FLAB) is an annual… Read More »

Non-Biological Complex Drugs (NBCDs) and their follow-on versions: time for an editorial section

Published in: Volume 4 / Year 2015 / Issue 4
Author(s): , , , , , , , ,
Page: 167-70

Author byline as per print journal: Jon SB de Vlieger, PhD; Professor Stefan Mühlebach, PhD; Vinod P Shah, PhD; Scott E McNeil, PhD; Professor Gerrit Borchard, PharmD, PhD; Vera Weinstein, PhD; Beat Flühmann,… Read More »

Substantial savings with generics in Austria – and still room for more

Published in: Volume 4 / Year 2015 / Issue 3
Author(s):
Page: 141-2

Abstract: Austria has seen considerable savings with generics, due to its unique pricing system. Generic medicine penetration is, however, not as advanced as in other European countries. Additional savings could… Read More »

Page 1 of 3 1 2 3 Next »
Go Back Print